Recombinant Human Janus Kinase 2, GST-His-tagged

• Cat.No.: JAK2-5441H
• Product Overview: Recombinant humanJAK2, containing the catalytic and the pseudo kinase domain (aa 532-1132),with N-terminal GST-His Tag.

Specification

• Cat. No.: JAK2-5441H
• Description: JAK2 is a member ofintracellular non-receptor tyrosine kinases that transduce cytokine-mediatedsignals via the JAK-STAT pathway. JAK2 has two near-identicalphosphate-transferring domains. One domain exhibits the kinase activity whilethe other stabilizes the JAK conformational structure. JAK2 is thepredominant JAK kinase activated in response to several growth factors andcytokines such as IL-3, GM-CSF and erythropoietin. JAK2 has been found to beconstitutively associated with the prolactin receptor and is required forresponses to gamma interferon.
• Source: Sf9 cells
• Species: Human
• Form: Liquid in 25 mMTris-HCl, pH 8.0 + 100 mM NaCl + 0.05% Tween-20 + 50% glycerol + 3 mM DTT.
• Molecular Weight: 99 kda
• Specific Activity: 0.2 U/µg. One unitis defined as the amount of enzyme that will phosphorylate 1 nmol of tyrosinesubstrate per minute at pH 7.4 and 30°C. Assay buffer: 50 mM HEPES, pH 7.4 +3 mM MgCl2 + 3 mM MnCl2 + 1 mM DTT + 3 µM Na-orthovanadate + 0.5 mM ATP + 30µg/ml Poly (Glu:Tyr) 4:1 substrate + 10 µg/ml recombinant JAK2.
• Storage: Stablefor 6 months in working aliquots at -80°C. Avoid repeated freeze-thaw cycles.
• OfficialSymbol: JAK2
• Tag: His&GST
• Protein length: 532-1132

Gene Information

• Gene Name: JAK2 Janus kinase 2 [ Homosapiens ]
• Synonyms: JAK2; Janus kinase 2; JTK10;tyrosine-protein kinase JAK2; Janus kinase 2 (a protein tyrosine kinase); EC2.7.10.2; JAK-2; OTTHUMP00000021024; OTTHUMP00000043260
• Gene ID: 3717
• mRNA Refseq: NM_004972
• Protein Refseq: NP_004963
• MIM: 147796
• UniProt ID: O60674
• Chromosome Location: 9p24
• Pathway: Adipocytokine signaling pathway; CXCR4-mediatedsignaling events; Chemokine signaling pathway; Cholinergic synapse; Delta-NotchSignaling Pathway; EGFR1 Signaling Pathway; EPO Receptor Signaling; ErbB2/ErbB3signaling events; ErbB4 signaling events; Growth hormone receptor signaling; Herpessimplex infection; IFN-gamma pathway; IL-2 Signaling Pathway; Immune System
• Function: ATP binding; Janus kinaseactivity; SH2 domain binding; acetylcholine receptor binding; growth hormonereceptor binding; insulin receptor substrate binding; interleukin-12 receptorbinding; non-membrane spanning protein tyrosine kinase activity; nucleotidebinding; peptide hormone receptor binding; phosphoinositide 3-kinase binding;transferase activity

Reviews

10/03/2020

Quick response from customer service.

05/12/2020

Product performed as expected.

08/07/2018

Satisfied with product quality.

Q&As

What role does JAK2 play in myeloproliferative neoplasms (MPNs)?

JAK2 mutations, particularly JAK2 V617F, are hallmarks of several MPNs, including polycythemia vera, essential thrombocythemia, and primary myelofibrosis. These mutations lead to uncontrolled cell proliferation.

How does JAK2 activation lead to downstream signal transduction?

Upon cytokine binding to its receptor, JAK2 becomes activated through phosphorylation. This activation leads to the phosphorylation and activation of STAT (Signal Transducers and Activators of Transcription) proteins, which then translocate to the nucleus and regulate gene expression.

What is the primary function of the JAK2 protein in cellular signaling?

JAK2 is a non-receptor tyrosine kinase that plays a pivotal role in cytokine signaling, mediating cellular responses to growth factors and various cytokines.

How is JAK2 involved in hematopoiesis and blood cell development?

JAK2 is crucial for hematopoiesis, especially in the signaling pathways of erythropoietin and thrombopoietin, which are essential for red blood cell and platelet production, respectively.

How does JAK2 interact with cytokine receptors, and what is its significance?

JAK2 associates with the intracellular domains of specific cytokine receptors. Upon cytokine binding, JAK2 becomes activated, leading to downstream signaling events. This interaction is vital for mediating cellular responses to various cytokines.

Are there therapeutic agents that target JAK2, and in what contexts are they used?

Yes, there are several JAK2 inhibitors, such as ruxolitinib and fedratinib, which are used to treat MPNs. They work by inhibiting the kinase activity of JAK2, thereby reducing aberrant cell proliferation.

Are there known mutations in the JAK2 gene, and what are their implications?

Yes, one of the most well-known mutations is JAK2 V617F, which results in constitutive activation of the kinase. This mutation is associated with various myeloproliferative neoplasms (MPNs).